Dx dialogues: 4 considerations in identifying patients for novel therapies for CKD
Nephrologist Sean Hashmi, MD, talks through what he considers when identifying patients for novel therapies for CKD and hyperphosphatemia.
Up Next
Dx dialogues: transcellular and paracellular transport inhibitors for CKD and hyperphosphatemia
Dx dialogues: exciting upcoming developments in the treatment of CKD
Managing CKD with chronic kidney disease
The importance of sleep while living with chronic kidney disease
Dx dialogues: new treatment advances & future treatments for COPD
How continued monitoring of kidney failure will help
Chronic kidney disease: 5 ways to build healthy eating habits
When to call your physician while living with kidney failure
Dx dialogues: versatile treatment options across the multiple myeloma landscape
Dx dialogues: cell replacement therapies for type 1 diabetes
